Patent ID: 11926674
Assignee: GENENTECH, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of treating goblet cell metaplasia and/or excess mucus, the method comprising administering to a subject in need thereof an effective amount of an antibody that binds to human Jagged2, wherein the antibody comprises:
a) amino acid residues 31-35 of SEQ ID NO: 88 as CDRH1, amino acid residues 50-65 of SEQ ID NO: 88 as CDRH2, amino acid residues 95-102 of SEQ ID NO: 88 as CDRH3, amino acid residues 24-34 of SEQ ID NO: 100 as CDRL1, amino acid residues 50-56 of SEQ ID NO: 100 as CDRL2, and amino acid residues 89-97 of SEQ ID NO: 100 as CDRL3;
b) amino acid residues 31-35 of SEQ ID NO: 89 as CDRH1, amino acid residues 50-65 of SEQ ID NO: 89 as CDRH2, amino acid residues 95-102 of SEQ ID NO: 89 as CDRH3, amino acid residues 24-34 of SEQ ID NO: 101 as CDRL1, amino acid residues 50-56 of SEQ ID NO: 101 as CDRL2, and amino acid residues 89-97 of SEQ ID NO: 101 as CDRL3;
c) amino acid residues 31-35 of SEQ ID NO: 90 as CDRH1, amino acid residues 50-65 of SEQ ID NO: 90 as CDRH2, amino acid residues 95-102 of SEQ ID NO: 90 as CDRH3, amino acid residues 24-34 of SEQ ID NO: 102 as CDRL1, amino acid residues 50-56 of SEQ ID NO: 102 as CDRL2, and amino acid residues 89-97 of SEQ ID NO: 102 as CDRL3; or
d) amino acid residues 31-35 of SEQ ID NO: 91 as CDRH1, amino acid residues 50-65 of SEQ ID NO: 91 as CDRH2, amino acid residues 95-102 of SEQ ID NO: 91 as CDRH3, amino acid residues 24-34 of SEQ ID NO: 103 as CDRL1, amino acid residues 50-56 of SEQ ID NO: 103 as CDRL2, and amino acid residues 89-97 of SEQ ID NO: 103 as CDRL3,
wherein the amino acid residue numbering is according to Kabat, and
wherein the goblet cell metaplasia and/or excess mucus is associated with asthma or chronic obstructive pulmonary disease (COPD).